Table 2.
Incidence and Risk of Serious Infection
| Full THIN Cohort | No Psoriasis N=954,315 |
All Psoriasis N=199,700 |
Mild Psoriasis N=187,258 |
Moderate-to-Severe Psoriasis N=12,442 |
|---|---|---|---|---|
|
| ||||
| Follow-up time (yrs) | ||||
| Mean (SD) | 6.4 (4.7) | 6.0 (4.7) | 6.1 (4.7) | 5.1 (4.0) |
| Median (IQR) | 5.5 (2.3, 9.8) | 5.0 (2.1, 9.4) | 5.1 (2.1, 9.5) | 4.2 (1.8, 7.5) |
|
| ||||
| Number of person-years | 6,096,846 | 1,207,499 | 1,143,873 | 63,625 |
|
| ||||
| Number (%) of serious infections | 47,875 (5.0) | 10,734 (5.4) | 9,807 (5.2) | 927 (7.5) |
|
| ||||
| Incidence per 10,000 person years (95% CI) | 78.5 (77.8, 79.2) | 88.9 (87.2, 90.6) | 85.7 (84.1, 87.4) | 145.7 (136.6, 155.4) |
|
| ||||
| Unadjusted hazard ratio (95% CI) | Reference | 1.14 (1.12, 1.16) | 1.10 (1.07, 1.12) | 1.97 (1.84, 2.10) |
|
| ||||
| Adjusted hazard ratio (95% CI)a | Reference | 1.21 (1.18, 1.23) | 1.18 (1.16, 1.21) | 1.63 (1.52, 1.75) |
|
| ||||
| iHOPE Cohort |
No Psoriasis N=83,540 |
All Psoriasis N=8,569 |
Mild Psoriasis N=4,437 |
Moderate-to-Severe Psoriasis N=4,132 |
|
| ||||
| Follow-up time (yrs) | ||||
| Mean (SD) | 4.1 (1.7) | 4.2 (1.6) | 4.2 (1.6) | 4.2 (1.6) |
| Median (IQR) | 4.4 (3.1, 5.6) | 4.4 (3.3, 5.6) | 4.4 (3.3, 5.6) | 4.4 (3.3, 5.5) |
|
| ||||
| Number of person-years | 342,169 | 35,664 | 18,435 | 17,229 |
|
| ||||
| Number (%) of serious infections | 2,588 (3.1) | 371 (4.3) | 180 (4.1) | 191 (4.6) |
|
| ||||
| Incidence per 10,000 person years (95% CI) | 75.6 (72.8, 78.6) | 104.0 (94.0, 115.2) | 97.6 (84.4, 113.0) | 110.9 (96.2, 127.8) |
|
| ||||
| Unadjusted hazard ratio (95% CI) | Reference | 1.38 (1.23, 1.53) | 1.29 (1.11, 1.50) | 1.47 (1.27, 1.70) |
|
| ||||
| Adjusted hazard ratio (95% CI)b | Reference | 1.21 (1.09, 1.35) | 1.16 (0.99, 1.35) | 1.27 (1.10, 1.47) |
CI, confidence interval; IQR, interquartile range; SD, standard deviation; yrs, years
Adjusted for age, sex, BMI, smoking and drinking status, asthma/COPD, CVD, CKD, CHF, dementia, depression, diabetes, IBD, liver disease, OA, RA, systemic corticosteroid use within 90 days prior to start date, flu and pneumonia vaccination status, hospitalization or infection within 30 days prior to start date, and Townsend score.
Adjusted for age, sex, BMI, smoking status, asthma/COPD, CVD, CKD, CHF, dementia, depression, diabetes, IBD, liver disease, OA, systemic corticosteroid use within 90 days prior to start date, flu and pneumonia vaccination status, hospitalization or infection within 30 days prior to start date.